Statistically significant variations in diagnostic testing, treatments, genetic testing, clinical trials and information needs by country p<0.05
| Country | First two reported tests carried out (n=2477) | Treatments (n=1430) | ||||||||
| CA125 | TVU | Abdominal ultrasound | CT | MRI | Women having any surgery | Women having upfront chemotherapy | Women having surgery for recurrence | Women having second surgery because first operation was not sufficient | Proportion of women having IP chemotherapy | |
| All respondents | 25.4% | 21.2% | 13.7% | 19.3% | 7.7% | 94.2% | 20.7% | 9.6% | 12% | 9.8% |
| Australia | 1.1% (p=0.000, z=−7.25) | 98.2% (p=0.004, z=2.88) | ||||||||
| Brazil | 3.9% (p=0.000, z=−4.32) | 16.7% (p=0.035, z=2.11) | 31.6% (p=0.002, z=3.14) | |||||||
| Canada | 24.6% (p=0.000, z=4.06) | 4.4% (p=0.012, z=−2.51) | ||||||||
| Germany | 13.6% (p=0.000, z=−4.84) | 28.8% (p=0.000, z=4.98) | 2.5% (p=0.000, z=−4.34) | |||||||
| Hungary | 36.7% (p=0.022, z=2.29) | 32.7% (p=0.017, z=2.39) | 6.1% (p=0.003, z=−3.02) | 11.2% (p=0.014, z=−2.47) | 59% (p=0.000, z=−5.2) | 28.1% (p=0.002, z=2.32) | ||||
| Italy | 38.5% (p=0.001, z=3.33) | 5% (p=0.000, z=−4.74) | 28.6% (p=0.011, z=2.53) | 0.6% (p=0.000, z=−8.66) | 4.1% (p=0.022, z=−2.29) | |||||
| Japan | 18.8% (p=0.002, z=−3.08) | 8.3% (p=0.000, z=−3.54) | 21.6% (p=0.000, z=6.51) | 3.7% (p=0.000, z=−3.73) | ||||||
| Spain | 14% (p=0.034, z=−2.12) | 98.5% (p=0.008, z=2.64) | 23.2% (p=0.019, z=2.35) | |||||||
| UK | 39.9% (p=0.000, z=4.74) | 15.5%(p=0.014, z=−2.45) | 23.4% (p=0.000, z=3.67) | 13% (p=0.003, z=−2.95) | 2.5% (p=0.000, z=−4.8) | 29.8% (p=0.016, z=2.41) | 4.3% (p=0.005, z=−2.91) | 0.7% (p=0.000, z=−8.17) | ||
| USA | 20.5% (p=0.026, z=−2.22) | 25.8% (p=0.048, z=1.98) | 25.1% (p=0.014, z=2.46) | 3.8% (p=0.001, z=−3.49) | 98.3% (p=0.000, z=3.85) | 14.8% (p=0.023, z=−2.27) | 22.5% (p=0.000, z=4.22) | |||
| | Genetic testing (n=1528) | Clinical trials (n=1340) | Information needs (n=1193) |
| Had a test after diagnosis | Proportion of women asked to join a clinical trial | Proportion of women who found all the information they needed at any point | |
| All respondents | 51.1% | 23.7% | 19.7% |
| Australia | 65.8% (p=0.002, z=3.17) | ||
| Brazil | 20.0% (p=0.000, z=−4.81) | ||
| Canada | 64.5% (p=0.001, z=3.27) | ||
| Germany | 41.3% (p=0.000, z=3.82) | 28.6% (p=0.030, z=2.17) | |
| Hungary | 20.7% (p=0.000, z=−5.54) | 4.4% (p=0.000, z=−4.35) | |
| Italy | 63.5% (p=0.021, z=2.31) | 34.7% (p=0.005, z=2.80) | |
| Japan | 5.0% (p=0.000, z=−23.65) | 12.5% (p=0.000, z=−4.27) | 4.2% (p=0.000, z=−7.93) |
| Spain | |||
| UK | 59.8% (p=0.032, z=2.14) | ||
| USA | 79.1% (p=0.000, z=9.41) | 25.7% (p=0.040, z=2.06) |
TVU, transvaginal ultrasound.